Compare 10X Genomics Inc (TXG) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard International High Dividend Yield ETF — how do they compare? 10X Genomics Inc trades at $80.65 (market cap $10.07B), while Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is far larger — about 2.3× 10X Genomics Inc's market cap, and Vanguard International High Dividend Yield ETF is more actively traded (748,441 versus 5,657,286). Which is the better fit depends on your goals — on Pluang, investors hold 10X Genomics Inc for 91 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| TXG | VYMI | |
|---|---|---|
Market Cap | $10.07B | $22.80B |
Volume | 5,657,286 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $97.74 | $107.13 |
52-Week Low | $11.48 | $82.92 |
Typical Hold Time | 91 Days | 50 Days |
Enterprise Value | $9.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.
The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.
VYMI, the Vanguard International High Dividend Yield ETF, trades at $100.06, down 0.17% on the day. Technical indicators are bearish overall, with moving averages signaling selling pressure, though oscillators are neutral. The ETF has attracted institutional buying interest and positive media coverage for its international diversification and dividend yield appeal, with a dividend of $0.82 scheduled for payment in September 2026.
The outlook for VYMI is supported by its focus on high-yield international stocks, particularly in financials, which benefit from rising global rates. Risks include exposure to international market volatility and currency fluctuations. Analyst sentiment is generally positive, highlighting its low fees and strong historical returns compared to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
